30 questions to ask a perinatal biologics supplier before you buy

Why evaluating a perinatal biologics supplier takes more than a phone call

Clinics buying Wharton's jelly allografts or exosome products are not buying a single product. Compare each product's source, processing records, applicable shipping conditions and lot documentation. A written question list, answered in writing, gives a practice something it can keep in a vendor file and compare across suppliers.

This list is organized by stage: donor screening, processing and testing, storage and shipping, regulatory documentation, and account setup. A practice does not need to ask all thirty questions on a first call, but every question should eventually have a documented answer before an order is placed. Treat the exercise as a procurement scorecard, not a sales conversation, and expect a credible perinatal biologics supplier to provide written answers or point to specific documents rather than give verbal assurances alone.

Donor screening and tissue recovery questions

The first set of questions concerns where the tissue comes from and how it was recovered. A supplier's answers here should be specific about process, not just a statement that donors are screened.

Ask for the underlying screening criteria rather than a summary, since the summary is what appears in marketing material and the criteria are what a regulatory reviewer would ask for.

• 1. Are donors consented at the time of a scheduled, full-term cesarean delivery, and is that consent documented separately from the medical record?
• 2. What medical and social history screening is performed on each donor before tissue is accepted?
• 3. What serology or infectious disease testing is run, and is a summary of results available per lot?
• 4. Does donation affect a mother's ability to also bank cord blood, and if so, how is that disclosed to donors?
• 5. Who recovers the tissue, and what training or licensure do those personnel hold?

Processing, sterility testing, and lot release questions

Processing and release testing are where a perinatal biologics supplier's internal quality system shows up as hard data rather than language. A practice should ask for the actual window between recovery and processing, the name of the lab used for sterility testing, and what happens to a lot that fails.

Ask which release process applies to each product and request the corresponding records. If a supplier cannot describe the release process for a lyophilized product as clearly as for a cryopreserved one, ask why.

• 6. How many hours elapse between tissue recovery and the start of processing?
• 7. Is sterility testing performed by a third-party laboratory, and is that lab named on the certificate of analysis?
• 8. Is each lot quarantined until testing is complete and internal release criteria are met?
• 9. What happens to a lot that fails sterility or release testing, and is that disposition documented?
• 10. Does every vial carry a unique lot identifier that traces back to a specific donor and processing run?

Cold chain, storage, and shipping questions

A product can meet every release specification at the point of manufacture and still arrive compromised if cold chain handling fails in transit. Ask how the supplier packages, ships, and verifies temperature control, and ask what recourse exists if a shipment arrives outside spec.

Shelf-stable, lyophilized formats shift some of these questions toward storage conditions and reconstitution handling rather than cryogenic handling, so tailor the list to the product family being purchased.

• 11. Are cryopreserved products frozen using a validated slow-rate freezing process and stored at a documented temperature?
• 12. Are shipments sent overnight on dry ice in a validated shipping container, and is that validation data available on request?
• 13. What should staff do if a shipment arrives with dry ice depleted or packaging compromised?
• 14. For lyophilized, shelf-stable formats, what are the storage temperature range and shelf life stated in the product insert?
• 15. Is there a documented process for reporting a temperature excursion back to the supplier, and does it trigger a replacement or investigation?

Regulatory framework and documentation questions

Request written product-specific regulatory documentation and review it with counsel. Ask a perinatal biologics supplier to produce, not just describe, its registration and licensure documentation, and ask directly how it positions each product under federal rules.

For Wharton's jelly products, the supplier positions each product under its HCT/P framework. Whether a specific intended use meets all applicable criteria in 21 CFR 1271.10 is a determination for the clinic and its counsel, not the distributor. For exosome products, FDA states that no exosome product is FDA approved. These products are generally regulated as biologic drugs under section 351 of the Public Health Service Act, and purchase and clinical-use decisions belong to the physician, working with the physician's own regulatory counsel. This list and this article are not legal advice; a practice evaluating its own regulatory exposure should work with qualified FDA regulatory counsel.

These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.

• 16. Can the supplier produce establishment registration and tissue bank licensure documentation for review, rather than describe it in general terms?
• 17. How does the supplier characterize the regulatory status of its Wharton's jelly products, and does it acknowledge that whether a specific intended use meets the criteria in 21 CFR 1271.10 is a determination made by the clinic and its counsel?
• 18. Does the supplier state clearly that no exosome product is FDA approved, and that exosome products are generally regulated as biologic drugs under section 351 of the Public Health Service Act?
• 19. Does any product marketing reference specific diseases, conditions, or outcomes, and if so, is that a red flag worth escalating internally?
• 20. Is a certificate of analysis, donor eligibility summary, and lot release record available per lot before or at the time of shipment?

Account verification, ordering, and support questions

The final set of questions covers the practical mechanics of becoming a buyer: how accounts are verified, how orders are placed, and what kind of support a practice can expect after the sale. Because these products are sold only to licensed clinics, medspas operating under physician supervision, and physicians, account verification is itself a signal of how seriously a supplier treats compliance.

Confirm that PB pricing is available to verified accounts. Evaluate other suppliers against applicable requirements and their documented policies.

• 21. Is account verification tied to an NPI number, and how is that number checked against the NPPES registry?
• 22. Who at the practice is authorized to place orders, and does the supplier confirm that authorization before shipping?
• 23. Is pricing published openly, or is it only available to verified accounts after setup?
• 24. What form does post-sale support take, and is it limited to product documentation rather than clinical or dosing advice?
• 25. Is there a named contact for peer-to-peer conversations about product documentation, and is that distinct from a sales representative?

Scoring the answers and spotting red flags

Once a supplier has answered these categories, the practical step is scoring the responses rather than filing them away. A simple approach is to mark each category as fully documented, partially documented, or undocumented, and to require full documentation for donor screening, lot release, and regulatory status before a first order.

The remaining questions below cover documentation habits worth tracking after the first order is placed, as the relationship moves from sales conversation to ongoing account.

• 26. Will the supplier provide written answers to these questions, or only verbal ones?
• 27. Does documentation stay consistent across repeated requests, or do figures and claims shift between conversations?
• 28. Is there a single point of contact who owns documentation requests, or does every request restart with a new representative?
• 29. Does the supplier disclose which product family a document applies to, rather than sending generic materials across its catalog?
• 30. Would the supplier's documentation hold up if shown to outside regulatory counsel, rather than only to a purchasing manager?